Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy
MetadataShow full item record
Given that cancer is one of the main causes of death worldwide, many efforts have been directed toward discovering new treatments and approaches to cure or control this group of diseases. Chemotherapy is the main treatment for cancer; however, a conventional schedule based on maximum tolerated dose (MTD) shows several side effects and frequently allows the development of drug resistance. On the other side, low dose chemotherapy involves antiangiogenic and immunomodulatory processes that help host to fight against tumor cells, with lower grade of side effects. In this review, we present evidence that metronomic chemotherapy, based on the frequent administration of low or intermediate doses of chemotherapeutics, can be better than or as efficient as MTD. Finally, we present some data indicating that noncytotoxic concentrations of antineoplastic agents are able to both up-regulate the immune system and increase the susceptibility of tumor cells to cytotoxic T lymphocytes. Taken together, data from the literature provides us with sufficient evidence that low concentrations of selected chemotherapeutic agents, rather than conventional high doses, should be evaluated in combination with immunotherapy. Copyright © 2012 UICC.
How to cite this document
Showing items related by title, author, creator and subject.
Verona, Carlos Benedito; Zerati Filho, Miguel ; El Ammar Müller, Márcio; Almeida Calado, Adriano (Revista Brasileira de Medicina, 2004) [Artigo]The renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of ...
Buttros, Daniel de Araújo Brito ; Nahás, Eliana Aguiar Petri ; Vespoli, Heloísa Maria de Luca ; Uemura, Gilberto ; De Almeida, Bruno Da Rosa ; Nahas-Neto, Jorge (Menopause, 2013) [Artigo]The aim of this study was to assess the risk of metabolic syndrome (MetS) in postmenopausal breast cancer survivors as compared with postmenopausal women without breast cancer. METHODS: In this cross-sectional study, 104 ...
Dulley, Frederico Luiz; Saboya, Rosaura; de Moraes Hungria, Vãnia Tietsche; Bueno, Nadjanara Dorna; de Mello, Fernando Gomes ; Frota, Maria Tereza; Chiattone, Carlos Sergio; Barros, José Carlos; Mori, Nair Sumie; Sturaro, Daniel et al. (São Paulo Medical Journal, 2005) [Artigo]Context and Objective: Lipasomial daunorubicin has been used to treat hematological malignancies, including multiple myelomo (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and ...